Olanzapine is a prescription medication used primarily to treat schizophrenia and bipolar I disorder. It belongs to a class of drugs called atypical antipsychotics, and it works by blocking certain chemical signals in the brain that contribute to psychotic symptoms, mood instability, and disordered thinking. It’s available as a daily oral tablet, a dissolving tablet, and a long-acting injection given every two to four weeks.
Schizophrenia
Schizophrenia is the most common reason olanzapine is prescribed. The medication helps reduce hallucinations, delusions, and disorganized thinking by dampening overactive dopamine and serotonin signaling in the brain. For most people, the oral form is taken once daily, and symptom improvement typically begins within the first few weeks of treatment.
For people who have difficulty taking a daily pill or who benefit from more consistent drug levels, a long-acting injectable version exists. This formulation is injected into the muscle every two to four weeks by a healthcare professional, and it requires that a person first show they tolerate the oral version before switching. The injectable form is only approved for schizophrenia, not for bipolar disorder or other conditions.
Bipolar I Disorder
Olanzapine is effective for treating acute manic and mixed episodes in bipolar I disorder. In a controlled trial of 115 patients, it was significantly more effective than placebo at reducing manic symptoms, and this held true regardless of whether psychotic features were present. It can be used during the intense high of a manic episode to help stabilize mood and behavior, then continued as part of longer-term management.
When bipolar disorder shifts to its depressive phase, olanzapine alone is less helpful. But a combination pill pairing olanzapine with fluoxetine (an antidepressant) is specifically approved for depressive episodes in bipolar I disorder. In two eight-week trials, this combination outperformed both olanzapine alone and placebo at reducing depression scores. The combination is sold under the brand name Symbyax.
Treatment-Resistant Depression
The same olanzapine-fluoxetine combination carries a second approval: treatment-resistant depression. This applies to people with major depressive disorder who haven’t responded to at least two different antidepressants at adequate doses during their current episode. Across three clinical studies involving nearly 600 patients, the combination produced significantly greater improvements in depression compared to either olanzapine or fluoxetine taken alone. This is typically a later-line option, reserved for cases where standard antidepressants haven’t worked.
Use in Adolescents
Olanzapine is sometimes prescribed to teenagers for schizophrenia or bipolar I disorder, but with an important caveat: it should be part of a broader treatment plan that includes counseling and educational support. The metabolic side effects discussed below tend to be especially pronounced in younger patients, so the decision to use it in this age group involves careful weighing of benefits against risks.
Off-Label Uses
Olanzapine is sometimes prescribed for conditions it’s not officially approved to treat. These include anxiety disorders, behavioral disturbances in dementia, personality disorders, and PTSD. The evidence for most of these uses is limited. For behavioral issues in dementia, controlled trials have shown only small effects. For conditions like eating disorders and substance abuse, there is essentially no supporting evidence. Guidelines generally recommend considering olanzapine and similar medications off-label only after other treatments have failed.
How It Works in the Brain
Olanzapine affects multiple chemical messaging systems at once, which is partly why it’s useful across several conditions but also why it produces a wide range of side effects. Its strongest actions are blocking dopamine receptors (which helps reduce psychotic symptoms and mania) and serotonin receptors (which may contribute to mood stabilization and reduce some of the movement side effects seen with older antipsychotics). It also interacts with receptors involved in alertness and the body’s fight-or-flight system, which helps explain why drowsiness is common, especially early in treatment.
Weight Gain and Metabolic Effects
Weight gain is one of the most significant concerns with olanzapine and the side effect most likely to affect your daily life. Studies have reported average weight gain of up to 26 pounds, making olanzapine one of the most weight-promoting medications in its class. This isn’t just a cosmetic issue. The added weight often comes with rises in blood sugar and cholesterol, increasing your risk for type 2 diabetes and heart disease over time.
Because of these risks, treatment guidelines call for regular metabolic monitoring throughout your time on the medication. The typical schedule looks like this:
- Weight and BMI: checked at baseline, then at weeks 4, 8, and 12, and every three months after that
- Blood sugar: checked at baseline, again around 12 weeks, and at least once a year going forward
- Cholesterol and lipids: checked at baseline, again around 12 weeks, and yearly for those at higher cardiovascular risk
If you notice rapid weight gain in the first few months, that’s worth raising with whoever prescribes the medication. Some people manage the effect through diet and exercise changes, while others may need to switch to a different medication with a lower metabolic burden.
Important Safety Warning for Older Adults
Olanzapine carries a boxed warning, the most serious type of FDA safety alert, regarding use in elderly patients with dementia-related psychosis. Across 17 placebo-controlled trials, older adults with dementia who took atypical antipsychotics had a 1.6 to 1.7 times higher risk of death compared to those on placebo. Over a typical 10-week trial, the death rate was about 4.5% in the treated group versus 2.6% in the placebo group. Deaths were mostly cardiovascular (heart failure, sudden death) or infectious (pneumonia). Olanzapine is not approved for treating dementia-related behavioral problems, and this risk applies to the entire class of atypical antipsychotics, not just olanzapine specifically.